Novel biological therapies for the treatment of multiple myeloma
- 31 December 2005
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Haematology
- Vol. 18 (4), 619-634
- https://doi.org/10.1016/j.beha.2005.01.010
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological ActivityMayo Clinic Proceedings, 2004
- Arsenic trioxide is effective in the treatment of multiple myeloma in SCID miceEuropean Journal of Haematology, 2004
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasiasExpert Opinion on Investigational Drugs, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Thalidomide in the Treatment of Relapsed Multiple MyelomaMayo Clinic Proceedings, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Safety and antitumor activity of recombinant soluble Apo2 ligandJCI Insight, 1999
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences of the United States of America, 1994